CAS 572924-54-0

Ridaforolimus

Description:

Ridaforolimus, with the CAS number 572924-54-0, is a synthetic compound that belongs to the class of mTOR (mammalian target of rapamycin) inhibitors. It is primarily used in the field of oncology for its potential therapeutic effects against various types of cancer. Ridaforolimus functions by inhibiting the mTOR pathway, which plays a crucial role in regulating cell growth, proliferation, and survival. This inhibition can lead to reduced tumor growth and enhanced apoptosis in cancer cells. The compound is typically administered via intravenous infusion and has been studied in clinical trials for its efficacy in treating soft tissue sarcomas and other malignancies. Ridaforolimus is characterized by its specific molecular structure, which includes a macrolide backbone similar to that of rapamycin, contributing to its biological activity. As with many targeted therapies, its use may be associated with side effects, including immunosuppression and metabolic changes, necessitating careful monitoring during treatment.

Formula: C₅₃H₈₄NO₁₄P

InChI: InChI=1/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI key: InChIKey=BUROJSBIWGDYCN-GAUTUEMISA-N

SMILES: O=C1N2[C@](C(=O)O[C@]([C@@H](C[C@H]3C[C@@H](OC)[C@H](OP(C)(C)=O)CC3)C)(CC(=O)[C@H](C)/C=C(\C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@@H](OC)C[C@]4(O[C@@](O)(C1=O)[C@H](C)CC4)[H])[H])(CCCC2)[H]

Synonyms:

• 42-(Dimethylphosphinate)rapamycin
• Ap 2357
• Ap 23573
• Mk 8669
• Rapamycin, 42-(dimethylphosphinate)
• Ridaforolimus
• Deforolimus
• Deforolimus (AP23573)
• Ridaforolimus (Deforolimus, MK8669, AP23573)
• AP23573; MK-8669; RIDAFOROLIMUS; AP 23573; MK 8669; AP-23573; MK8669
• Deforolimus/MK-8669/AP23573
• Deforolimus (AP23573, MK-8669)
• DeforoliMus(AP 23573,MK-8669,RidaforoliMus)
• DeforoliMus(MK-8669)
• RidaforoliMus (DeforoliMus, MK-8669)
• deforolimus 572924-54-0
• Deforolimus (AP23573)42-
• Ridaforolimus, &gt
• RidaforoliMus, >80%
• DeforoliMus (RidaforoliMus)
• AP 23573, MK 8669, 42-DiMethylphosphinate-rapaMycin
• 42-(Dimethylphosphinate)rapamycin USP/EP/BP
• DeforoliMus API
• Ridaforolimus (MK-8669)
• Ridaforolimus Deforolimus
• RapaMycin,42-(diMethylphosphinate) (9CI)

Ridaforolimus

CAS: 572924-54-0

Ridaforolimus

Purity: ≥90%

Molecular weight: 990.21g/mol

Ref: 54-BUP10198

Rapamycin Impurity 23 (Ridaforolimus)

CAS: 572924-54-0

Formula: C₅₃H₈₄NO₁₄P

Molecular weight: 990.22

Ref: 4Z-R-1837

Ridaforolimus

CAS: 572924-54-0

Ridaforolimus (AP23573) 是亲脂性大环内酯类抗生素雷帕霉素的小分子非前药类似物，具有潜在的抗肿瘤活性。它是一种有效和选择性的 mTOR 抑制剂，在 HT-1080 细胞中抑制 S6 磷酸化的 IC50值为 0.2 nM。

Formula: C₅₃H₈₄NO₁₄P

Purity: 90.00% - 98.55%

Color and Shape: Off-White Solid

Molecular weight: 990.21

Ref: TM-T6334

Ridaforolimus, >80%

Controlled Product

CAS: 572924-54-0

Applications An immunosupressant and is currently being investigated for use in cancer treatments. Ridaforolimus may act as a regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival. Ridaforolimus, was formerly known as Deforolimus. Potent mTORC1 inhibitor.
References Gadducci, A., et al.: Gynecol. Endocrinol., 24, 239 (2008), Gridelli, C., et al.: Oncol., 13, 139 (2008), Mita, M., et al.: J. Clin. Oncol., 26, 361 (2008), Hartford, C., et al.: Clin. Canc. Res., 15, 1428 (2009),

Formula: C₅₃H₈₄NO₁₄P

Purity: >80%

Color and Shape: Neat

Molecular weight: 990.21

Ref: TR-R495850

Deforolimus

CAS: 572924-54-0

mTOR inhibitor; anti-tumoral

Formula: C₅₃H₈₄NO₁₄P

Purity: Min. 95%

Molecular weight: 990.21 g/mol

Ref: 3D-FD111870